Comparison ASP Herceptin vs biosimilars U.S. 2025

Comparison of the average sales price (ASP) of Herceptin vs biosimilars in the United States as of the fourth quarter 2025 (in U.S. dollars)

Comparison of ASP Herceptin vs biosimilars in the U.S. Q4 2025

Last update:

Jan 20, 2026

Author:

��ƽ�� Research Department

Region:

United States of America

Survey time period:

Q4 2025

As of the fourth quarter of 2025, the average sales price of cancer drug Herceptin was U.S. dollars, compared to U.S. dollars for biosimilar drug Herzuma. Biosimilars were able to reduce the price significantly.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Comparison of the average sales price (ASP) of Herceptin vs biosimilars in the United States as of the fourth quarter 2025 (in U.S. dollars)

Get in touch with us for additional information

��ƽ��